Navigation Links
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
Date:10/26/2011

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011

http://www.reportlinker.com/p0332346/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-in-Pharmaceuticals---October-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the last six months.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 8

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2011 8

2.2 Pharmaceuticals & Healthcare, Global, Top Deals, September 2011 10

2.2.1 Couckinvest to Acquire Additional Stake In Omega Pharma For $1.3 Billion 10

2.2.2 Sanofi Prices Public Offering Of Senior Unsecured Notes Due 2014 For $1 Billion 10

2.2.3 Fresenius Medical Care Prices Private Placement Of Senior Unsecured Notes For $950 Million 10

2.2.4 Evotec Enters Into Co-Development Agreement With Roche 11

2.2.5 f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 11

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, September 2011 12

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13

3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2011 13

3.1.1 Top M&A Deals in September 2011 14

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2011–September 2011 15

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2011 16

3.2.1 Top Equity Offering Deals in September 2011 17

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2011 – September 2011 18

3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, September 2011 19

3.3.1 Top Debt Offering Deals in September 2011 20

3.3.2 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, April 2011 – September 2011 21

3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2011 22

3.4.1 Top PE/VC Deals in September 2011 23

3.4.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2011 24

3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2011 25

3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2011 – September 2011 26

3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2011 – September 2011 27

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2011 28

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2011 28

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2011 – September 2011 29

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2011 30

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2011 31

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 32

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), April 2011 – September 2011 33

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 34

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2011 35

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2011 35

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 36

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2011 37

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, August 2011 37

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, August 2011 38

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2011 – September 2011 39

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2011 – September 2011 40

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2011 – September 2011 41

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2011 – September 2011 42

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 43

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2011 43

6.1.1 Oncology – Deals of the Month 44

6.2 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2011 45

6.2.1 Infectious Diseases – Deals of the Month 46

6.3 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2011 47

6.3.1 Central Nervous System – Deals of the Month 48

6.4 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, September 2011 49

6.4.1 Metabolic Disorders – Deals of the Month 50

6.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2011 51

6.5.1 Cardiovascular – Deals of the Month 52

6.6 Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2011 53

6.6.1 Immunology – Deals of the Month 54

6.7 Pharmaceuticals & Healthcare, Global, Respiratory, Deals, September 2011 55

6.7.1 Respiratory – Deals of the Month 56

7 Deal Summary by Geography 57

7.1 Pharmaceuticals & Healthcare, North America Deals, September 2011 57

7.1.1 North America – Deals of the Month 58

7.2 Pharmaceuticals & Healthcare, Europe, Deals, September 2011 59

7.2.1 Europe – Deals of the Month 60

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2011 61

7.3.1 Asia-Pacific – Deals of the Month 62

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2011 63

7.4.1 Rest of the World – Deals of the Month 64

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 65

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2011 – September 2011 65

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2011 – September 2011 66

9 Further Information 67

9.1 Methodology 67

9.2 About GlobalData 68

9.3 Contact Us 68

9.4 Disclosure information 68

9.5 Disclaimer 68

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 9

Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, September 2011 10

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2011 12

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 14

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2011 14

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2011 – September 2011 15

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 16

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2011 17

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 18

Table 10: Pharmaceuticals & Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 19

Table 11: Pharmaceuticals & Healthcare, Global, Top Debt Offering Deals, September 2011 20

Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), April 2011 – September 2011 21

Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 22

Table 14: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2011 23

Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2011 – September 2011 24

Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2011 25

Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 26

Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2011 – September 2011 27

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 28

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 29

Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 30

Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 31

Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 32

Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2011 – September 2011 33

Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2011 – September 2011 34

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 35

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 36

Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, September 2011 37

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, August 2011 37

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, August 2011 38

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), April 2011 – September 2011 39

Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2011 40

Table 33: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2011 – September 2011 41

Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2011 42

Table 35: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 44

Table 36: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 46

Table 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 48

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 50

Table 39: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 52

Table 40: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 54

Table 41: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 56

Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 58

Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 60

Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 62

Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 63

Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 65

Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 66

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 8

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),September 2011 12

Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2011 – September 2011 15

Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 16

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 18

Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 19

Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 21

Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 22

Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2011 – September 2011 24

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), September 2011 25

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 26

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 28

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 29

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 30

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 32

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2011 – September 2011 33

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 34

Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 35

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 36

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 39

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2011 – September 2011 40

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), April 2011 – September 2011 41

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2011 42

Figure 25: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 43

Figure 26: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 45

Figure 27: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 47

Figure 28: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 49

Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 51

Figure 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 53

Figure 31: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 55

Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 57

Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 59

Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 61

Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 63

Figure 36: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 65

Figure 37: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2011 – September 2011 66

To order this report:

Investment Banking Industry: Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011

Investment Banking Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011
2. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
3. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
4. Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver
5. HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market
6. MGT Capital Investments, Inc.s Plan of Compliance Accepted by NYSE AMEX, LLC
7. MGT Capital Investments, Inc. Provides Update on Recent Developments
8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
9. Apax Partners, CPPIB and PSP Investments to Acquire Kinetic Concepts, Inc. for $68.50 per Share
10. Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years
11. MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
(Date:2/8/2016)... -- --> --> ... Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) ... Gynecology) - Global Forecasts to 2020", published by MarketsandMarkets, ... period of 2015 to 2020. The market is expected ... 10.5% from 2015 to 2020. Browse 73 ...
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and ... pancreatic cancer. , Gary D. Radine, who recently retired as president and CEO of ... Society’s 2015 CEO of the Year , helped lead the effort to raise ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research ... U.S. require dental technicians to be certified or obtain continuing education. To increase ... the “What’s In Your Mouth?” campaign to inform dentists and patients about the ...
Breaking Medicine News(10 mins):